

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

Stéphanie Dulucq,^{1,2} Franck E. Nicolini,^{2,3,4} Delphine Rea,^{2,5} Pascale Cony-Makhoul,^{2,6} Aude Charbonnier,^{2,7} Martine Escoffre-Barbe,^{2,8} Valérie Coiteux,^{2,9} Pascal Lenain,^{2,10} Françoise Rigal-Huguet,^{2,11} Jixing Liu,^{2,12} Agnès Guerci-Bresler,^{2,13} Laurence Legros,^{2,14} Jean-Christophe Ianotto,^{2,15} Martine Gardembas,^{2,16} Pascal Turlure,^{2,17} Viviane Dubruille,^{2,18} Philippe Rousselot,^{2,19} Juliana Martiniuc,^{2,20} Henry Jardel,^{2,21} Hyacinthe Johnson-Ansah,^{2,22} Bertrand Joly,^{2,23} Tawfiq Henni,^{2,24} Emilie Cayssials,^{2,25} Patricia Zunic,^{2,26} Marc G. Berger,^{2,27} Bruno Villemagne,^{2,28} Fanny Robbesyn,¹ Stephane Morisset,³ François-Xavier Mahon^{2,29#} and Gabriel Etienne^{2,29#}

¹Laboratory of Hematology, University Hospital of Bordeaux, Hôpital Haut Lévêque, Pessac; ²Groupe Fi-LMC, Centre Léon Bérard, Lyon; ³INSERM U1052, Centre de Recherche de Cancérologie de Lyon, Centre Léon Bérard, Lyon; ⁴Hematology Department, Centre Léon Bérard, Lyon; ⁵Adult Hematology Department, Hôpital Saint Louis, Paris; ⁶Hematology Department & Clinical Investigation Center, Centre Hospitalier Annecy-Genevois, Metz-Tessy, Pringy; ⁷Hematology Department, Institut Paoli-Calmettes, Marseilles; ⁸Hematology Department, CHU de Pontchaillou, Rennes; ⁹Hematology Department, CHU Huriez, Lille; ¹⁰Hematology Department, Institut Henri Becquerel, Rouen; ¹¹Hematology Department, Institut Universitaire du Cancer, CHU de Toulouse, Toulouse; ¹²Hematology & Oncology Department, Centre Hospitalier de Valence, Valence; ¹³Hematology Department, CHRU Brabois, Nancy; ¹⁴Hematology Department, Hôpital Bicêtre, Le Kremlin-Bicêtre; ¹⁵Hematology Department, Morvan Hospital, CHU, Brest; ¹⁶Hematology Department, CHU, Angers; ¹⁷Hematology Department, CHU Dupuytren, Limoges; ¹⁸Hematology Department, Hôtel Dieu, Nantes; ¹⁹Hematology Department, Centre Hospitalier de Versailles, Le Chesnay; ²⁰Hematology Department, Centre Hospitalier de Saint Briec, Saint Briec; ²¹Hematology Department, Centre Hospitalier de Bretagne, Vannes; ²²Institute of Normandy, CHU de la Côte de Nacre, Caën; ²³Hematology Department, CH Sud Francilien, Corbeil-Essonnes; ²⁴Hematology Department, CHR La Réunion; ²⁵Hematology Department, CHU de Poitiers, Poitiers; ²⁶Hematology Department, Centre Hospitalier, Saint Pierre de La Réunion; ²⁷Hematology (Biology) Department, CHU Estaing, Clermont-Ferrand; ²⁸Internal Medicine and Onco-hematology Department, La Roche sur Yon and ²⁹Hematology Department, Institut Bergonié, Bordeaux, France

[#]F-XM and GE contributed equally as co-senior authors.

Correspondence: S. Dulucq
stephanie.dulucq@chu-bordeaux.fr

Received: February 8, 2022.

Accepted: May 18, 2022.

Prepublished: May 26, 2022.

<https://doi.org/10.3324/haematol.2022.280811>

©2022 Ferrata Storti Foundation

Published under a CC BY-NC license



Tableau 1S: Baseline characteristics of 199 patients enrolled in STIM2 study

Variables	n=199
Age, at CML diagnosis median (min;max)	55 (15-84)
Age at STIM2 inclusion median (min;max)	60 (24-90)
Gender, N (%)	
-F	110 (55.3%)
-M	89 (44.7%)
Sokal score, N (%)	
-Low	82 (41.2%)
-Intermediate	74 (37.2%)
-High	30 (15.1%)
-Unknown	13 (6.5)
ELTS score, N (%)	
-Low	135 (67.8%)
-Intermediate	18 (9%)
-High	8 (4%)
-Unknown	38 (19.1%)
Type of transcript N (%)	
-e14a2	89 (44.7%)
-e13a2	52 (26.1%)
-e14a2 + e13a2	29(14.6%)
-Unknown	29 (14.6%)
DMR duration median (min;max)	38.3 (22.95-124.3)
Imatinib duration median (min;max)	77.1 (38.4;149.9)
ddPCR <i>BCR::ABL1</i> N (%)	
-<0.0023% ^{IS}	137 (68.8%)
-≥0.0023% ^{IS}	37 (18.6%)
-Unknown	15 (12.6%)

Figure 1S: TFS for patients without relapse at 6 months (A) or 24 months (B)

